Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia

被引:39
作者
Carvalho, G.
Fabre, C.
Braun, T.
Grosjean, J.
Ades, L.
Agou, F.
Tasdemir, E.
Boehrer, S.
Israel, A.
Veron, M.
Fenaux, P.
Kroemer, G.
机构
[1] Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France
[2] INSERM, Unit Apoptosis Canc & Immun, Villejuif, France
[3] Univ Paris 11, Fac Med Paris Sud, Villejuif, France
[4] Univ Paris 13, AP HP, Hop Avicenne, Hematol Unit, Bobigny, France
[5] Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Activities Cellulaires, Paris, France
[6] Inst Pasteur, CNRS, URA 2582, SMAC, Paris, France
关键词
apoptosis; NF-kappa B; mitochondria;
D O I
10.1038/sj.onc.1210043
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), blasts constitutively activate the antiapoptotic transcription factor nuclear factor-kappa B (NF-kappa B). Here, we show that this NF-kappa B activation relies on the constitutive activation of the I kappa B kinase (IKK) complex, which is formed by the IKK alpha, IKK beta and IKK gamma/NF-kappa B essential modulator (NEMO) subunits. A cell-permeable peptide that mimics the leucine zipper subdomain of IKK gamma, thus preventing its oligomerization, inhibited the constitutive NF-kappa B activation and induced apoptotic cell death in a panel of human MDS and AML cell lines (P39, MOLM13, THP1 and MV4-11). Small interfering RNA-mediated knockdown of the p65 NF-kappa B subunit or the three IKK subunits including IKK gamma/NEMO also induced apoptotic cell death in P39 cells. Cell death induced by the IKK gamma/NEMO-antagonistic peptide involved the caspase-independent loss of the mitochondrial transmembrane potential as well as signs of outer mitochondrial membrane permeabilization with the consequent release of cytochrome c, apoptosis-inducing factor and endonuclease G. Primary bone marrow CD34(+) cells from high-risk MDS and AML patients also succumbed to the IKK gamma/NEMO-antagonistic peptide, but not to a mutated control peptide. Altogether, these data indicate that malignant cells in high-risk MDS and AML cells critically depend on IKK gamma/NEMO to survive. Moreover, our data delineate a novel procedure for their therapeutic removal, through inhibition of IKK gamma/NEMO oligomerization.
引用
收藏
页码:2299 / 2307
页数:9
相关论文
共 30 条
[1]   Inhibition of NF-κB activation by peptides targeting NF-κB essential modulator (NEMO) oligomerization [J].
Agou, F ;
Courtois, G ;
Chiaravalli, J ;
Baleux, F ;
Coïc, YM ;
Traincard, F ;
Israël, A ;
Véron, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (52) :54248-54257
[2]   The trimerization domain of nemo is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains [J].
Agou, F ;
Traincard, F ;
Vinolo, E ;
Courtois, G ;
Yamaoka, S ;
Israël, A ;
Véron, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :27861-27869
[3]   Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream [J].
Arkin, MR ;
Wells, JA .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :301-317
[4]   Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts [J].
Baumgartner, B ;
Weber, M ;
Quirling, M ;
Fischer, C ;
Page, S ;
Adam, M ;
von Schilling, C ;
Waterhouse, C ;
Schmid, C ;
Neumeier, D ;
Brand, K .
LEUKEMIA, 2002, 16 (10) :2062-2071
[5]   Targeting NF-κB in hematologic malignancies [J].
Braun, T ;
Carvalho, G ;
Fabre, C ;
Grosjean, J ;
Fenaux, P ;
Kroemer, G .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (05) :748-758
[6]  
Braun T, 2006, BLOOD, V107, P1156
[7]   Quantitation of mitochondrial alterations associated with apoptosis [J].
Castedo, M ;
Ferri, K ;
Roumier, T ;
Métivier, D ;
Zamzami, N ;
Kroemer, G .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 265 (1-2) :39-47
[8]  
Castedo M, 1996, J IMMUNOL, V157, P512
[9]   Making protein interactions druggable: Targeting PDZ domains [J].
Dev, KK .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1047-1056
[10]   Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy [J].
Dombret, H ;
Fenaux, P ;
Soignet, SL ;
Tallman, MS .
SEMINARS IN HEMATOLOGY, 2002, 39 (02) :8-13